Context: Cytomegalovirus (CMV) infection enhances hepatitis C virus (HCV) pathogenesis as it prevents the normal mechanisms which are responsible for HCV clearance, thus plays a key role in HCV persistence and pathogenicity. Aims: An individual develops lifetime CMV (immunoglobulin G [IgG]) seropositivity, after primary infection after which CMV establishes latency with intermittent reactivation. Thus, the present study was undertaken to look for coinfection of CMV (IgG) in HCV seropositive cases in the hospital.
Background: Coronavirus disease-2019 (COVID-19) is a recently emerged viral disease, for which there’s currently no definitive treatment. It is, therefore, necessary to determine biomarkers to know the extent of disease severity so that timely action can be taken to reduce mortality. We aimed to determine the usefulness of C-reactive protein (CRP) levels in assessing COVID-19 disease severity and correlate them with mortality due to the same. Methods: Data for COVID-19 were retrospectively collected and analyzed from May 2020 to October 2020. The CRP value was correlated with disease severity using Karl Pearson’s correlation coefficient. A logistic regression model was adopted to analyze the association between mortality and related factors. Results: Out of 642 patients enrolled, 22 died while 620 recovered. Most of the non-survivors were male. Multivariate analysis showed that age, diabetes, hypertension, and CRP values were significantly associated with mortality. CRP showed a strong positive correlation with disease severity and, hence, mortality. Conclusion: In patients with COVID-19, CRP correlated with disease severity and tended to be a good predictor of adverse outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.